These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 7947238

  • 1. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF.
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [Abstract] [Full Text] [Related]

  • 2. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B.
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
    Luboldt W, Henneberg-Quester KB, Schaefer UW, Beelen DW, Quabeck K, Thraenhart O.
    Beitr Infusionsther; 1990 Sep; 26():190-3. PubMed ID: 1703827
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
    Vamvakas EC.
    Transfus Med Rev; 2005 Jul; 19(3):181-99. PubMed ID: 16010649
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
    Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S.
    Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
    [Abstract] [Full Text] [Related]

  • 12. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, Masouridi-Levrat S, Duchosal MA, Niederhauser C.
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [Abstract] [Full Text] [Related]

  • 13. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group.
    Gilbert GL, Hayes K, Hudson IL, James J.
    Lancet; 1989 Jun 03; 1(8649):1228-31. PubMed ID: 2566781
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.